HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $180 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $180.
December 26, 2023 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics' stock may see a positive impact in the short term due to the reiterated Buy rating and maintained price target of $180 by HC Wainwright & Co.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can influence investor sentiment and stock prices. The reiteration of a Buy rating and a high price target suggests a strong conviction in the company's potential, which could lead to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100